Topics

EyeGate Pharmaceuticals, Inc.: EyeGate Files IDE with FDA for PRK Pivotal Study

07:08 EDT 2 May 2019 | FinanzNachrichten

WALTHAM, MA / ACCESSWIRE / May 2, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ('EyeGate' or 'the Company') announced today it has successfully submitted the Investigational Device Exemption...

Original Article: EyeGate Pharmaceuticals, Inc.: EyeGate Files IDE with FDA for PRK Pivotal Study

NEXT ARTICLE

More From BioPortfolio on "EyeGate Pharmaceuticals, Inc.: EyeGate Files IDE with FDA for PRK Pivotal Study"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...